raltegravir

Type: Keyphrase
Name: raltegravir
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

An integrase inhibitor such as raltegravir may reduce immune activation in early therapy

Facebook Twitter Google + Email PrintA new study shows that an initial early treatment using the integrase inhibitor raltegravir (Isentress) leads to less immune activation in people with HIV than initial treatment with other drugs, including those ... [Published Project Inform - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Revision: 22, Authorised

Entities: Isentress, raltegravir
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

HIV/AIDS: What New Treatment Options Are Available?

In an article I wrote earlier this year, I shared some optimism from the medical and scientific community about the possibility of a cure for HIV.LIKE BlackDoctor.org on Facebook! Get Your Daily Medicine…For LIFE!Research continues, but new studies indicate ... [Published BlackDoctor.org - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 2 reports

HIV May Protect Against Multiple Sclerosis

New research supports an association between HIV infection and a reduced risk for multiple sclerosis (MS).Investigators at the Prince of Wales Hospital in Sydney, Australia, and Queen Mary University of London, United Kingdom, found that having HIV infection ... [Published General Medicine eJournal - Aug 06 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

[Articles] Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ... [Published The Lancet online - Aug 05 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Raltegravir Regimen More Durable, Atazanavir Less Durable, Than Single-Tablet Atripla

20th International AIDS ConferenceJuly 20-25, 2014Melbourne, Australia Tweet 20th International AIDS Conference, July 20-25, 2014, Melbourne IAC: Economic Burden of Adverse Events Associated With HIV Antiretroviral Therapy in the United States (07/30/14) ... [Published National AIDS Treatment Advocacy Project - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Charcot Project: INSPIRE Trial fully recruited

The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ... [Published Multiple Sclerosis Research - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Merck & Co sees Q2 profit rocket

Merck & Co has seen earnings more than double for the second quarter of the year, after a vigorous spout of cost-cutting and a one-time gain from AstraZeneca ($741 million), after it bought out the US group's interest in Nexium and Prilosec, helped swell ... [Published Pharma Times - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

AIDS 2014: Dolutegravir Demonstrates Good Efficacy Despite Resistance

Details Category: Approved HIV Drugs Published on Tuesday, 29 July 2014 00:00 Written by Liz HighleymanAntiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression ... [Published HIV and Hepatitis.com - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Merck's revenue drops 1% but still beats analysts' estimates for 2nd-qtr

Global revenue at pharma giant Merck & Co (NYSE: MRK) slipped 1% but the company has still exceeded analysts’ estimates for the second quarter of 2014.Over the period, revenue stood at $10.9 billion, which compares favorably with analysts’ expectations ... [Published Pharma Letter - Jul 29 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

HARNESS study: ritonavir-boosted atazanavir (ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients

20th International AIDS ConferenceJuly 20-25, 2014Melbourne, Australia Tweet Reported by Jules Levin20th International AIDS Conference, Melbourne, Australia, July 20Ð25, 2014J. van Lunzen1, A. Pozniak2, J. Gatell3, A. Antinori4, I. Klauck5, O. Serrano6, ... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Raltegravir Not Better Than NRTIs for Refractory HIV

Raltegravir offers no benefits over nucleoside reverse-transcriptase inhibitors (NRTIs) when used in combination with a protease inhibitor (PI) as second-line HIV therapy, according to an open-label, randomized study published in the July 17 issue of ... [Published Diabetes Care - Jul 23 2014]

Quotes

...has built a valuable infectious disease pipeline over the past several years," said Jay R Luly, Ph D , President and Chief Executive Officer. "Regulatory approval is expected in the U S and in Europe for our protease inhibitor ABT-450 as part of AbbVie's HCV combination regimen, our NS5A inhibitor EDP-239 has advanced into combination studies with Novartis and we continue our research on our proprietary cyclophilin and nucleotide inhibitors. Outside of HCV, our compound EDP-788 for MRSA has advanced in its clinical trials and we continue to explore other disease areas where we can apply our internal drug discovery and development expertise."
"Further investigation of our finding has the potential, after more than 170 years since MS was first described... to reveal the (causes) of MS" they said
According to the news editors, the research concluded: "Structural studies of this three-domain RSV IN in complex with viral DNA may be feasible."
...Ronald Valdiserri, Assistant Secretary for Health, Infectious Diseases. "The research presented at AIDS 2014 brings us closer toward achieving the goals of both the Viral Hepatitis Action Plan and the National HIVHIV AIDSAIDS Strategy."

More Content

All (61) | News (43) | Reports (0) | Blogs (18) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Enanta Pharmaceuticals Updates on 3rd Quarter F... [Published Pharmacy Choice - Aug 18 2014]
Could HIV drugs help treat multiple sclerosis? [Published Nursing Times - Aug 18 2014]
Peripheral Neuropathy in Primary HIV Infection [Published General Medicine eJournal - Aug 18 2014]
Nonoccupational Postexposure Prophylaxis for HI... [Published General Medicine eJournal - Aug 18 2014]
Cipla consolidated net dips by 39% in Q1 [Published PharmaBiz - Aug 16 2014]
HIV May Help Prevent Multiple Sclerosis [Published Sudan Vision Daily - Aug 13 2014]
Researchers at University of Minnesota Target H... [Published 4 Traders - Aug 13 2014]
Researchers Find Hepatitis C Cures Effective fo... [Published BlackAIDS.org - Aug 12 2014]
An integrase inhibitor such as raltegravir may ... [Published Project Inform - Aug 12 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
HIV/AIDS: What New Treatment Options Are Availa... [Published BlackDoctor.org - Aug 08 2014]
HIV May Protect Against Multiple Sclerosis [Published General Medicine eJournal - Aug 06 2014]
Could HIV drugs help treat or prevent MS? [Published Multiple Sclerosis Trust - Aug 06 2014]
Could HIV drugs help treat multiple sclerosis? [Published Cotswold Journal - Aug 05 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
HIV may help prevent multiple sclerosis [Published Yahoo! News - Aug 05 2014]
20th International AIDS Conference Highlights [Published POZ.com - Aug 04 2014]
Raltegravir Regimen More Durable, Atazanavir Le... [Published National AIDS Treatment Advocacy Project - Aug 01 2014]
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
Merck & Co sees Q2 profit rocket [Published Pharma Times - Jul 29 2014]
AIDS 2014: Dolutegravir Demonstrates Good Effic... [Published HIV and Hepatitis.com - Jul 29 2014]
Merck's revenue drops 1% but still beats analys... [Published Pharma Letter - Jul 29 2014]
Translational challenges in targeting latent HI... [Published National AIDS Treatment Advocacy Project - Jul 29 2014]
3D Hepatitis C Combo Effective in HIV Patients [Published EverydayHealth.com - Jul 29 2014]
HARNESS study: ritonavir-boosted atazanavir (AT... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
Neurocognitive Disorder Rates Differ by US vs L... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
No Detectable HIV RNA or DNA in 2 Bone Marrow T... [Published National AIDS Treatment Advocacy Project - Jul 26 2014]
Oral Hepatitis C Drugs Helping Patients Coinfec... [Published Medscape Women's Health - Jul 25 2014]
Gilead Sciences' (GILD) CEO John Martin on Q2 2... [Published Yahoo! Finance - Jul 24 2014]
Raltegravir Not Better Than NRTIs for Refractor... [Published Diabetes Care - Jul 23 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ...
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ...
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jul 15 2014]
Merck begins patient enrollment in Phase III tr... [Published PBR - News - Jun 06 2014]
Merck has started patient enrollment in its global Phase III clinical trial 'ONCEMRK', which is evaluating a once-daily investigational formulation of Isentress (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.